EA200801520A1 - CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) - Google Patents
CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13)Info
- Publication number
- EA200801520A1 EA200801520A1 EA200801520A EA200801520A EA200801520A1 EA 200801520 A1 EA200801520 A1 EA 200801520A1 EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A EA200801520 A EA 200801520A EA 200801520 A1 EA200801520 A1 EA 200801520A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- human interleukin
- chemical
- antibodies against
- humanized antibodies
- against human
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
- C07K16/244—Interleukins [IL]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/02—Nasal agents, e.g. decongestants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/02—Antiprotozoals, e.g. for leishmaniasis, trichomoniasis, toxoplasmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
- A61P33/10—Anthelmintics
- A61P33/12—Schistosomicides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/10—Cells modified by introduction of foreign genetic material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
- C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Abstract
Настоящее изобретение относится к иммуноглобулинам, в частности антителам, специфично связывающим человеческий интерлейкин-13 (hlL-13). Антитела по изобретению могут быть применены в лечении множества заболеваний или расстройств, чувствительных к модуляции взаимодействия между hlL-13 и рецептором человеческого IL-13. Такие заболевания включают тяжелую астму, атопический дерматит, хроническую обструктивную болезнь легких (ХОБЛ) и различные фиброзные заболевания. Также раскрыты фармацевтические композиции, содержащие указанные антитела, и способы их изготовления.The present invention relates to immunoglobulins, in particular antibodies specifically binding human interleukin-13 (hlL-13). The antibodies of the invention can be used in the treatment of a variety of diseases or disorders sensitive to the modulation of the interaction between hlL-13 and the receptor for human IL-13. Such diseases include severe asthma, atopic dermatitis, chronic obstructive pulmonary disease (COPD) and various fibrosis diseases. Also disclosed are pharmaceutical compositions containing these antibodies, and methods for their manufacture.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GBGB0600488.1A GB0600488D0 (en) | 2006-01-11 | 2006-01-11 | Immunoglobulins |
PCT/EP2007/050219 WO2007080174A2 (en) | 2006-01-11 | 2007-01-10 | Chimeric and humanised anti-human il-13 antibodies |
Publications (1)
Publication Number | Publication Date |
---|---|
EA200801520A1 true EA200801520A1 (en) | 2009-02-27 |
Family
ID=35997844
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA200801520A EA200801520A1 (en) | 2006-01-11 | 2007-01-10 | CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) |
Country Status (18)
Country | Link |
---|---|
EP (1) | EP1976881A2 (en) |
JP (1) | JP2009523154A (en) |
KR (1) | KR20080113201A (en) |
CN (1) | CN101370829A (en) |
AR (1) | AR058955A1 (en) |
AU (1) | AU2007204372A1 (en) |
BR (1) | BRPI0706481A2 (en) |
CA (1) | CA2635972A1 (en) |
CR (1) | CR10161A (en) |
EA (1) | EA200801520A1 (en) |
GB (1) | GB0600488D0 (en) |
IL (1) | IL192207A0 (en) |
MA (1) | MA30156B1 (en) |
NO (1) | NO20082767L (en) |
PE (1) | PE20081185A1 (en) |
TW (1) | TW200736274A (en) |
WO (1) | WO2007080174A2 (en) |
ZA (1) | ZA200805526B (en) |
Families Citing this family (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2532678A1 (en) | 2005-10-21 | 2012-12-12 | Novartis AG | Human antibodies against il13 and therapeutic uses |
NZ572565A (en) | 2006-05-25 | 2011-04-29 | Glaxo Group Ltd | Modified humanised anti-interleukin-18 antibodies |
EP2050764A1 (en) * | 2007-10-15 | 2009-04-22 | sanofi-aventis | Novel polyvalent bispecific antibody format and uses thereof |
SG171733A1 (en) * | 2008-11-26 | 2011-07-28 | Glaxo Group Ltd | Ligands that bind il-13 |
NZ594514A (en) | 2009-03-05 | 2013-06-28 | Abbott Lab | Interleukin-17 BINDING PROTEINS |
GB0904214D0 (en) | 2009-03-11 | 2009-04-22 | Ucb Pharma Sa | Biological products |
AU2010251955A1 (en) * | 2009-05-28 | 2011-12-22 | Glaxo Group Limited | IL-13 binding protein |
MX2012004711A (en) | 2009-10-20 | 2012-05-23 | Abbott Lab | Isolation and purification of anti-il-13 antibodies using protein a affinity chromatography. |
CN103328506A (en) * | 2010-10-15 | 2013-09-25 | 米迪缪尼有限公司 | Therapies for improving pulmonary function |
BR112013013460A8 (en) | 2010-12-16 | 2019-02-12 | Genentech Inc | methods for identifying an asthma patient, method for monitoring an asthma patient, use of a total periostin detection kit, total periostin measurement kit, use of an anti-il-13 antibody, use of a therapeutically amount lebrikizumab therapy, use of a th2 pathway inhibitor, adverse event evaluation method, anti-periostin antibody, and total periostin test |
PL3235508T3 (en) | 2011-03-16 | 2021-07-12 | Sanofi | Compositions comprising a dual v region antibody-like protein |
WO2015061441A1 (en) | 2013-10-23 | 2015-04-30 | Genentech, Inc. | Methods of diagnosing and treating eosinophilic disorders |
KR20160124165A (en) | 2014-02-21 | 2016-10-26 | 제넨테크, 인크. | Anti-il-13/il-17 bispecific antibodies and uses thereof |
CA2943326A1 (en) | 2014-04-11 | 2015-10-15 | Novartis Ag | Methods of selectively treating asthma using il-13 antagonists |
WO2016149276A1 (en) | 2015-03-16 | 2016-09-22 | Genentech, Inc. | Methods of detecting and quantifying il-13 and uses in diagnosing and treating th2-associated diseases |
EP3433615A1 (en) | 2016-03-21 | 2019-01-30 | Institut National de la Sante et de la Recherche Medicale (INSERM) | Methods for diagnosis and treatment of solar lentigo |
US20190359722A1 (en) * | 2017-01-23 | 2019-11-28 | Toyo University | Anti-epha2 antibody and immunological detection of epha2 using same |
CN109776677B (en) * | 2017-11-15 | 2023-11-03 | 尚华科创投资管理(江苏)有限公司 | Humanized anti-IL-13 antibody and preparation method and application thereof |
CN107909501B (en) * | 2017-12-05 | 2020-12-01 | 创新先进技术有限公司 | Smell and behavior association method, smell social method and device |
CA3088557C (en) | 2018-02-09 | 2024-02-27 | Genentech, Inc. | Therapeutic and diagnostic methods for mast cell-mediated inflammatory diseases |
WO2020092015A1 (en) | 2018-11-02 | 2020-05-07 | University Of Rochester | Therapeutic mitigation of epithelial infection |
CN114008079A (en) * | 2019-03-20 | 2022-02-01 | 贾夫林肿瘤学公司 | anti-ADAM12 antibodies and chimeric antigen receptors, and compositions and methods comprising the same |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2003260748A1 (en) * | 2002-08-30 | 2004-03-19 | Glaxo Group Limited | Il-14 vaccine for the treatment of asthma and atopic disorders |
WO2004096849A2 (en) * | 2003-04-25 | 2004-11-11 | University Of Manitoba | Peptide-based cytokine/chemokine vaccines against allergy |
SG10201900535UA (en) * | 2003-12-23 | 2019-02-27 | Genentech Inc | Novel anti-il 13 antibodies and uses thereof |
US7501121B2 (en) * | 2004-06-17 | 2009-03-10 | Wyeth | IL-13 binding agents |
TWI307630B (en) * | 2004-07-01 | 2009-03-21 | Glaxo Group Ltd | Immunoglobulins |
-
2006
- 2006-01-11 GB GBGB0600488.1A patent/GB0600488D0/en not_active Ceased
-
2007
- 2007-01-09 TW TW096100833A patent/TW200736274A/en unknown
- 2007-01-09 AR ARP070100082A patent/AR058955A1/en unknown
- 2007-01-09 PE PE2007000018A patent/PE20081185A1/en not_active Application Discontinuation
- 2007-01-10 WO PCT/EP2007/050219 patent/WO2007080174A2/en active Application Filing
- 2007-01-10 EA EA200801520A patent/EA200801520A1/en unknown
- 2007-01-10 KR KR1020087019555A patent/KR20080113201A/en not_active Application Discontinuation
- 2007-01-10 CN CNA2007800022973A patent/CN101370829A/en active Pending
- 2007-01-10 JP JP2008549873A patent/JP2009523154A/en active Pending
- 2007-01-10 AU AU2007204372A patent/AU2007204372A1/en not_active Abandoned
- 2007-01-10 CA CA002635972A patent/CA2635972A1/en not_active Abandoned
- 2007-01-10 EP EP07703766A patent/EP1976881A2/en not_active Withdrawn
- 2007-01-10 BR BRPI0706481-0A patent/BRPI0706481A2/en not_active IP Right Cessation
-
2008
- 2008-06-16 IL IL192207A patent/IL192207A0/en unknown
- 2008-06-16 NO NO20082767A patent/NO20082767L/en not_active Application Discontinuation
- 2008-06-24 ZA ZA200805526A patent/ZA200805526B/en unknown
- 2008-07-11 MA MA31108A patent/MA30156B1/en unknown
- 2008-07-17 CR CR10161A patent/CR10161A/en not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AR058955A1 (en) | 2008-03-05 |
MA30156B1 (en) | 2009-01-02 |
CN101370829A (en) | 2009-02-18 |
KR20080113201A (en) | 2008-12-29 |
NO20082767L (en) | 2008-10-06 |
TW200736274A (en) | 2007-10-01 |
WO2007080174A3 (en) | 2007-12-06 |
EP1976881A2 (en) | 2008-10-08 |
JP2009523154A (en) | 2009-06-18 |
WO2007080174A2 (en) | 2007-07-19 |
GB0600488D0 (en) | 2006-02-22 |
ZA200805526B (en) | 2009-10-28 |
IL192207A0 (en) | 2008-12-29 |
BRPI0706481A2 (en) | 2011-03-29 |
CA2635972A1 (en) | 2007-07-19 |
AU2007204372A1 (en) | 2007-07-19 |
PE20081185A1 (en) | 2008-10-07 |
CR10161A (en) | 2008-11-26 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA200801520A1 (en) | CHEMICAL AND HUMANIZED ANTIBODIES AGAINST HUMAN INTERLEUKIN-13 (IL-13) | |
SG153878A1 (en) | Chimeric and humanised monoclonal antibodies against inteleukin-13 | |
CY1120033T1 (en) | ILL-4 AND / OR IL-13 AND ITS USES | |
CY1120874T1 (en) | INTERLEUKIN ANTIBODY SYNTHESIS-13 | |
EA201000785A1 (en) | COMPOSITIONS FOR DELIVERY IN LIGHT | |
MX340696B (en) | Anti-c5a antibodies and methods for using the antibodies. | |
WO2007045477A3 (en) | Human antibodies against il-13 and therapeutic uses | |
WO2008097461A3 (en) | Hepcidin and hepcidin antibodies | |
MX2009010765A (en) | Anti-ige antibodies. | |
UA95478C2 (en) | Humanized c-kit antibody | |
WO2007113172A3 (en) | Antibodies against amyloid-beta peptide | |
WO2010021874A3 (en) | Engineered anti-il-13 antibodies, compositions, methods and uses | |
EA201290849A1 (en) | OPTIMIZED MONOCLONAL ANTIBODIES AGAINST THE TISSUE FACTOR INHIBITOR (TFPI) | |
WO2010038155A3 (en) | Antibodies against il-25 | |
WO2007003421A3 (en) | Humanised antibodies specific for nogo-a and pharmaceutical uses thereof | |
WO2008042941A3 (en) | Humanized anti-ephb4 antibodies and their use in treatment of oncology and vasculogenesis-related disease | |
TNSN08175A1 (en) | Human antibodies against il-13 and therapeutic uses | |
TH83335A (en) | Immunoglobulin | |
TH83335B (en) | Immunoglobulin | |
TH97785A (en) | Immunoglobulin | |
TW200610768A (en) | IL-13 binding antibodies |